Laigo Bio closes €17M seed to advance SureTACs
The Next Web
Read full postLaigo Bio has secured €17 million in seed funding to develop its SureTACs technology, aiming to advance targeted cancer therapies. The investment will support preclinical development and preparation for clinical trials.



